Latest UCB Inc. Stories
ATLANTA, June 9, 2011 /PRNewswire/ -- UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into the marketing and promotion of KeppraÂ®, an anti-epileptic prescription medicine.
BALTIMORE, May 31, 2011 /PRNewswire/ -- UCB announced findings of the first cost-effectiveness analysis of VimpatÂ® (lacosamide) as add-on therapy for adults with uncontrolled partial-onset seizures.
ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) VimpatÂ® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7.
ATLANTA, Nov. 22, 2010 /PRNewswire/ -- New stories and insights from the epilepsy community have been unveiled on EpilepsyAdvocate.com, including new interviews on "Women Succeeding with Epilepsy" and Epilepsy Advocate Radio.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.